The FDA cited trial design concerns and lack of substantial evidence in denying approval for Replimune’s biologics license application in advanced melanoma. Replimune Group, Inc., announced that the ...
The complete response letter (CRL) was issued based on a pre-approval inspection at a third-party fill/finish manufacturer. Similar to other recent CRLs, this decision was made not based on the drug’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback